Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant
ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in monkeys were 3.2-fold and 2.3-fold of Molnupiravir, respectively Based on drug exposure relationship between monkeys and humans, oral double prodrug ASC10 is predicted to have...
‘2022 Sunhak Peace Prize Focuses on Vaccine Equity’
SEOUL, South Korea, Feb. 7, 2022 /PRNewswire/ -- On February 7, 2022, the Sunhak Peace Prize Committee (Chairman Jose Manuel Barroso, former President of the European Commission) will announce the 2022 Sunhak Peace Prize laureates are Dame Sarah Catherine Gilbert (age 59), Professor of Vaccinology at University of Oxford and Gavi, the Vaccine Alliance. Sarah Gilbert Gavi Professor...
Clarivate Identifies Seven Medtech Trends to Watch in 2022
LONDON, Feb. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new report, Outlook on the Medtech Industry: Seven Areas to Watch. The report analyzes seven factors that Clarivate analysts believe will be key for medtech markets...
Laekna Launched the new domain name www.laekna.com
SHANGHAI and WARREN, N.J., Feb. 7, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai Co., Ltd.), an emerging innovative biotech based in China's "Zhangjiang Pharma Valley" and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, today announced the...
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that ATG-037 has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia...
The one-component Sputnik Light vaccine has been authorized in India; over 2.5 billion people live in countries that approved Sputnik Light as a standalone vaccine and a universal booster
Sputnik Light will be an important part of India's vaccination program and the fight against mutations of COVID, including Omicron. Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people. MOSCOW, Feb. 7, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign...
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, Feb. 7, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Health Sciences Authority (HSA) of Singapore has approved Trodelvy®(sacituzumab govitecan or SG) for the treatment of adult patients with unresectable locally advanced...
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors The first U.S. patient is expected to be dosed in the first half of 2022 ASC61 shows significant antitumor efficacy as a single agent in various animal models ...
Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise
SINGAPORE, Feb. 5, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. The acquisition means that Genesis will be able to add J-Valve, a...
Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report
SYDNEY, Feb. 4, 2022 /PRNewswire/ -- Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the 2021 CenterWatch Global Site Relationship Benchmark Survey. Report available here CenterWatch, established in 1994, is a global benchmarking authority for the clinical trials sector. The benchmarking report...
